Patents by Inventor Amir S. Khan

Amir S. Khan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9452285
    Abstract: Aspects of the present invention relate to electroporation devices and methods of using same to effectively facilitate the introduction of a biomolecule into cells of a selected tissue in a body, in particular skin such as intradermic or subcutaneous tissue. In some aspects, the present invention is a skin EP device, which produces a pulse of energy and delivers same to the skin tissue using a skin electrode array and maintains a constant current in the same skin tissue based on user input, including a preset current, and allows the storage and acquisition of current waveform data.
    Type: Grant
    Filed: October 17, 2007
    Date of Patent: September 27, 2016
    Assignee: VGX Pharmaceuticals, Inc.
    Inventors: Ruxandra Draghia-Akli, Amir S. Khan
  • Patent number: 9156891
    Abstract: Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a, including for example, NS4B, NS5A and NS5B. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: October 13, 2015
    Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.
    Inventors: David B. Weiner, Krystle A. Lang-Kuhs, Jian Yan, Ruxandra Draghia-Akli, Amir S. Khan
  • Publication number: 20150166612
    Abstract: Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a, including for example, NS4B, NS5A and NS5B. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.
    Type: Application
    Filed: November 24, 2014
    Publication date: June 18, 2015
    Inventors: David B. Weiner, Krystle A. Lang-Kuhs, Jian Yan, Ruxandra Draghia-Akli, Amir S. Khan
  • Patent number: 8927508
    Abstract: There are provided methods of generating antibodies in a mammal against recombinant antigens using DNA plasmids capable of expressing said antigens in cells of said mammal, comprising: injecting into tissue of said mammal a DNA plasmid comprising an encoding sequence operably linked to a promoter, electroporating said tissue with an electroporation device capable of delivering an electrical pulse effective to electroporate cells of said tissue to allow entry of said DNA plasmid and expression of said antigen, and allowing said mammal to respond to said expressed antigen in order to generate antibodies to said antigen. Furthermore, there are provided methods of isolating antibodies specific against desired antigens wherein said antibodies are generated in a mammal using DNA plasmids capable of expressing said antigens.
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: January 6, 2015
    Assignee: VGX Pharmaceuticals, Inc.
    Inventors: Ruxandra Draghia-Akli, Amir S. Khan
  • Patent number: 8921536
    Abstract: Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a, including for example, NS4B, NS5A and NS5B. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.
    Type: Grant
    Filed: October 20, 2011
    Date of Patent: December 30, 2014
    Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.
    Inventors: David B Weiner, Krystle Lang, Jian Yan, Ruxandra Draghia-Akli, Amir S Khan
  • Patent number: 8209006
    Abstract: An electroporation device which may be used to effectively facilitate the introduction of a macromolecule into cells of a selected tissue in a body or plant. The electroporation device comprises an electro-kinetic device (“EKD”) whose operation is specified by software or firmware. The EKD produces a series of programmable constant-current pulse patterns between electrodes in an array based on user control and input of the pulse parameters and allows the storage and acquisition of current waveform data. The electroporation device also comprises a replaceable electrode disk having an array of needle electrodes, a central injection channel for an injection needle, and a removable guide disk.
    Type: Grant
    Filed: September 8, 2003
    Date of Patent: June 26, 2012
    Assignee: VGX Pharmaceuticals, Inc.
    Inventors: Louis C. Smith, Ruxandra Draghia-Akli, Amir S. Khan, Robert H. Carpenter, Jeff Darnell
  • Publication number: 20120093863
    Abstract: Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a, including for example, NS4B, NS5A and NS5B. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.
    Type: Application
    Filed: October 20, 2011
    Publication date: April 19, 2012
    Inventors: David B. WEINER, Krystle LANG, Jian YAN, Ruxandra DRAGHIA-AKLI, Amir S. KHAN
  • Patent number: 8058253
    Abstract: This invention is related to compositions and methods for decreasing cholesterol levels in a subject. The method utilizes a nucleic acid expression construct that encodes a growth-hormone-releasing-hormone (“GHRH”) that is delivered into a tissue of the subject, wherein, GHRH is expressed in vivo in the subject.
    Type: Grant
    Filed: July 5, 2007
    Date of Patent: November 15, 2011
    Assignee: VGX Pharmaceuticals, Inc.
    Inventors: Ruxandra Draghia-Akli, Amir S. Khan, Marta L. Fiorroto
  • Publication number: 20100010467
    Abstract: This invention is related to compositions and methods for decreasing cholesterol levels in a subject. The method utilizes a nucleic acid expression construct that encodes a growth-hormone-releasing-hormone (“GHRH”) that is delivered into a tissue of the subject, wherein, GHRH is expressed in vivo in the subject.
    Type: Application
    Filed: July 5, 2007
    Publication date: January 14, 2010
    Applicant: VGX PHARMACEUTICLAS, INC.
    Inventors: Ruxandra Draghia-Akli, Amir S. Khan, Marta L. Fiorroto
  • Publication number: 20090156787
    Abstract: There are provided methods of generating antibodies in a mammal against recombinant antigens using DNA plasmids capable of expressing said antigens in cells of said mammal, comprising: injecting into tissue of said mammal a DNA plasmid comprising an encoding sequence operably linked to a promoter, electroporating said tissue with an electroporation device capable of delivering an electrical pulse effective to electroporate cells of said tissue to allow entry of said DNA plasmid and expression of said antigen, and allowing said mammal to respond to said expressed antigen in order to generate antibodies to said antigen. Furthermore, there are provided methods of isolating antibodies specific against desired antigens wherein said antibodies are generated in a mammal using DNA plasmids capable of expressing said antigens.
    Type: Application
    Filed: November 14, 2008
    Publication date: June 18, 2009
    Applicant: VGX PHARMACEUTICALS, INC.
    Inventors: Ruxandra Draghia-Akli, Amir S. Khan